JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 31 No. 11 1802-1810
© 1990 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Massuger, L. F.A.G.
Right arrow Articles by Corstens, F. H.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massuger, L. F.A.G.
Right arrow Articles by Corstens, F. H.M.

Immunoscintigraphy of Ovarian Cancer with Indium-111-Labeled OV-TL 3 F(ab')2 Monoclonal Antibody

Leon F.A.G. Massuger, Peter Kenemans, Roland A.M.J. Claessens, René H.M. Verheijen, Charles P.T. Schijf, Simon P. Strijk, Lambert G. Poels, René G.C.M. van Hoesel and Frans H.M. Corstens

Departments of Obstetrics and Gynecology, Nuclear Medicine, Radiology, Cell Biology and Histology, and Medical Oncology, University Hospital Nijmegen, Nijmegen, The Netherlands
Department of Obstetrics and Gynecology, Free University Hospital, Amsterdam, The Netherlands

Correspondence: For reprints contact: Prof. Dr. F.H.M. Corstens, Dept. of Nuclear Medicine, University Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands.

ABSTRACT

The safety and diagnostic accuracy of immunoscintigraphy with the indium-111-labeled monoclonal antibody OV-TL 3 F(ab')2 (111In-OV-TL 3 F(ab')2) for diagnosis and follow-up of ovarian cancer was prospectively studied in 31 patients. Planar and SPECT scintigraphy were performed up to 4 days after i.v. injection of 140 MBq 111In-OV-TL 3 F(ab')2. Surgical evaluation was possible in 22 out of 31 patients. Imaging results were compared with X-ray computed tomography, ultrasound, and CA 125 serum level using the histologically confirmed surgical findings as a "gold standard." Apart from a transient rash observed in two patients, no other immediate or delayed adverse reactions were observed. Within the surgically evaluated group, ovarian cancer lesions were detected in 16 out of 17 patients (94%). Of 45 distinct tumor deposits found at operation, 67% were detected and localized with immunoscintigraphy while X-ray computed tomography and ultrasound visualized 53% and 23%, respectively.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1990 by the Society of Nuclear Medicine.